lawsuit

Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.

The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.

The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.

PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.

The company's cofounders will pay $500,000 each to settle allegations by the US Department of Justice that they submitted false claims to Medicare.

Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.

The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.

CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.